Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the
breast. The lump or mass is usually painless, hard & irregular but
it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple
discharge, nipple retraction and presence of breast skin changes (eg
peau d' orange, nipple excoriation, scaling, inflammation, skin
tethering, ulceration, abscess).
A combination of the CDK 4/6 inhibitor abemaciclib with fulvestrant improved overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC), with a trend toward improved outcomes in patients with poor prognosis, according to results of the phase III MONARCH 2* trial presented at ESMO 2019.
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.
Patients with HER2+ breast cancer with disease progression despite ≥2 lines of HER2-directed therapy may improve their progression-free survival (PFS) with the addition of neratinib than lapatinib to capecitabine, according to the phase III NALA* trial.
Annual breast cancer screening with magnetic resonance imaging (MRI) led to detection of fewer late-stage and node-positive cancers than annual mammography, according to the FaMRIsc* study from the Netherlands. However, specificity was lower and number of false-positives higher with MRI vs mammography.
The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.
New drug applications approved by US FDA as of 16 - 31 May 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.
Adding the selective oestrogen-receptor downregulator fulvestrant to the aromatase inhibitor anastrozole in the first-line setting significantly extends long-term progression-free survival (PFS) and overall survival (OS) compared with anastrozole alone in postmenopausal women with hormone-receptor (HR)-positive metastatic breast cancer, according to the final results of the S0226 trial.
Thalassaemia becomes a global health problem. Most women with thalassaemia trait can be picked up by universal prenatal screening for thalassaemia using mean corpuscular volume/haemoglobin, followed by haemoglobin pattern with or without DNA analysis.